We believe purposeful partnerships can change the world
We know we are not the only ones that want to see the revolutionary science of mRNA therapeutics transform lives. Partnerships with pharmaceutical, other biotechnology companies and non-profit organizations who share our mission, help extend the reach of our technology to impact more people globally.
We are always looking for new strategic partnerships that can help take our mRNA technology to the next level and into the hands of those who need it most.
Current Strategic Partnerships
Lilly and CureVac are collaborating on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary antigen-coding mRNA therapeutics. The companies will use CureVac's mRNA technology that targets tumor neoantigens for a more robust anti-cancer immune response.
Boehringer Ingelheim and CureVac collaborate to develop next generation lung cancer immunotherapy with CureVac’s CV9202 in different clinical settings. This partnership adds a highly innovative new approach to Boehringer Ingelheim’s lung cancer portfolio.
collaborates with CRISPR Therapeutics, a genome editing company
focused on creating transformative gene-based medicines for serious
diseases, and Casebia Therapeutics, a joint-venture established by
CRISPR Therapeutics and Bayer AG for developing CRISPR-based
therapeutics in select disease areas. Under the terms of the
agreement, CureVac will develop novel Cas9 mRNA constructs with
improved properties for gene editing applications, such as increased
potency, decreased duration of expression, and reduced potential for
The common goal of the partnership between CureVac and the Bill & Melinda Gates Foundation is to develop mRNA-based vaccines against various infectious diseases which have an enormous impact on global health.
CureVac has teamed up with CEPI to further develop The RNA PrinterTM prototype, a transportable, down-scaled, automated mRNA printing facility that can rapidly provide mRNA-based vaccine candidates for known pathogens. Under the partnership, CureVac will undertake the preclinical (and eventual phase 1 clinical) development of such candidate vaccines—prioritizing Lassa fever, rabies, and yellow fever.
CureVac has partnered with the Schepens Eye Research Institute of Massachusetts Eye and Ear, a teaching hospital of Harvard Medical School, to discover and develop novel mRNA-based candidates for undisclosed eye indications.
CureVac has entered into a Collaborative Research Agreement (“CRA”) with Yale University for discovery research into mRNA-based pulmonary therapeutic candidates. The exclusive CRA covers the development of an undisclosed number of novel mRNA-based candidates for pulmonary diseases.
In December 2019 Genmab and CureVac AG entered into a research collaboration and license agreement for the development of mRNA-based antibody therapeutics. The companies will collaborate on research to identify an initial product candidate, followed potentially by three additional programs, combining CureVac’s mRNA technology and know-how with Genmab’s proprietary antibody technologies and expertise.
See CureVac in action
Interested in a potential partnership? We’ll be at the following events and would welcome the opportunity to meet with any organization wanting to learn more about CureVac. Or please email us at firstname.lastname@example.org.